skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Why do we get Alzheimer's disease?

Abstract

Neurodegenerative diseases and Alzheimer's disease (AD) in particular, are among the major health concerns of the elderly in industrialized societies. The cause of AD is unknown and no disease-modifying treatments are available. The disease is characterized clinically by a progressive dementia and pathologically by the accumulation of protein aggregates in the brain and a profound loss of nerve cells. It has also become clear recently that local immune responses are activated in the AD brain and may have a role in the disease. Our laboratory uses genetic mouse models to understand the disease process and to identify potential therapeutic targets.

Authors:
Publication Date:
Research Org.:
SLAC (SLAC National Accelerator Laboratory (SLAC), Menlo Park, CA (United States))
Sponsoring Org.:
USDOE Office of Science (SC)
OSTI Identifier:
987523
DOE Contract Number:
AC02-76SF00515
Resource Type:
Multimedia
Resource Relation:
Conference: SLAC Public Lecture Series, SLAC National Accelerator Laboratory, Menlo Park, California, presented on October 02, 2006
Country of Publication:
United States
Language:
English
Subject:
43 PARTICLE ACCELERATORS

Citation Formats

Wyss-Coray, Tony. Why do we get Alzheimer's disease?. United States: N. p., 2006. Web.
Wyss-Coray, Tony. Why do we get Alzheimer's disease?. United States.
Wyss-Coray, Tony. Mon . "Why do we get Alzheimer's disease?". United States. https://www.osti.gov/servlets/purl/987523.
@article{osti_987523,
title = {Why do we get Alzheimer's disease?},
author = {Wyss-Coray, Tony},
abstractNote = {Neurodegenerative diseases and Alzheimer's disease (AD) in particular, are among the major health concerns of the elderly in industrialized societies. The cause of AD is unknown and no disease-modifying treatments are available. The disease is characterized clinically by a progressive dementia and pathologically by the accumulation of protein aggregates in the brain and a profound loss of nerve cells. It has also become clear recently that local immune responses are activated in the AD brain and may have a role in the disease. Our laboratory uses genetic mouse models to understand the disease process and to identify potential therapeutic targets.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2006},
month = {10}
}

Multimedia: